Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03865160
Other study ID # P001307
Secondary ID DRKS000233372020
Status Recruiting
Phase Phase 2/Phase 3
First received
Last updated
Start date October 19, 2021
Est. completion date April 2026

Study information

Verified date October 2022
Source University Eye Hospital, Freiburg
Contact Wolf Lagrèze, Prof.
Phone +49 (0) 761 270
Email wolf.lagreze@uniklinik-freiburg.de
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Myopia (nearsightedness) is the most common eye disorder. Only second to age, it is the main risk factor for major degenerative eye diseases such as glaucoma, macular degeneration or retinal detachment. Their risk increases with the degree of myopia. Hence, prevention of myopia and slowing its progression is of high relevance. Almost all clinical studies, including two large randomised clinical trials (RCT) were performed in Asia with Asian study participants. The results indicate that atropine eye drops can attenuate myopic progression in children, even in low concentrations thus minimizing unwanted side effects. However, the cumulative evidence is yet not strong enough to recommend their unrestricted use, especially in a Non-Asian population. We therefore intend to set up an adequately powered RCT comparing atropine 0.02% eye drops with placebo to validate previous findings and to test whether this therapeutic concept holds its promise in a European population.


Description:

Myopia (nearsightedness) is the most common developmental eye disorder in the first decades of life. It is the biggest risk factor for sight threatening degenerative eye diseases later in life, second only to age. Its prevalence is increasing worldwide in pandemic dimensions affecting now > 80% in Asian and > 40% in Caucasian populations. Myopia is one of the five eye diseases identified as immediate priorities by the WHO's global initiative for the elimination of avoidable blindness. It usually develops during primary school and its onset and progression are related to environmental factors such as near work and lack of day light exposure, to a lesser degree to genetic factors. Therefore, retardation of myopia progression is a major therapeutic goal. Clinical trials from Asia have shown that 0.01% atropine eye drops can attenuate progression of myopia while inducing only little side effects such as light sensitivity and reduced accommodation. Subsequent data also from Asia have suggested that a concentration of 0.05% atropine is slightly more effective with a still acceptable level of adverse effects. However, it is unclear whether this therapy is equally and sufficiently efficacious in a Caucasian population. It is also unclear which concentration of atropine represents the best compromise between efficacy and safety. Our own uncontrolled pilot data suggest that 0.01% delays progression by about 50% with negligible side effects, but that 0.05% induces a pupil dilation of > 3 mm, which is considered unacceptable. Due to the increasing prevalence also in Europe and an increasing demand from parents for means to retard myopia progression, the trial is the first European large scale randomized clinical trial investigating the safety and efficacy of 0.01% and 0.02% atropine eye drops in comparison to placebo drops. Such a trial is mandatory to substantiate the increasing off-label prescriptions of low-dose atropine in children and to develop clinical guidelines.


Recruitment information / eligibility

Status Recruiting
Enrollment 300
Est. completion date April 2026
Est. primary completion date October 2025
Accepts healthy volunteers No
Gender All
Age group 8 Years to 12 Years
Eligibility Inclusion Criteria: 1. Male or female patients aged 8 to 12 years (up to the day before the 13th birthday) 2. Myopia of -1 D to -6 D with reported or documented annual progression = 0.5 D of myopia 3. Written informed consent obtained from patient (if applicable) and parents or legal guardians according to international guidelines and local laws 4. Ability to understand the nature of the trial and the trial related procedures and to comply with them Exclusion Criteria: 1. Asian or African origin 2. Abnormal binocularity 3. Strabismus 4. Astigmatism >1.5 D 5. Anisometropia >1.5 D 6. History of amblyopia 7. Corrected visual acuity in any eye <0.63 8. Any acquired or developmental organic eye disease 9. Premature birth 10. Any known systemic metabolic disease or chromosomal anomaly 11. Previous use of any kind of contact lenses 12. Previous use of atropine eye drops 13. Epilepsy 14. Known hypersensitivity to the active substances or any of the excipients 15. Participation in any other interventional clinical trial within the last 30 days before the start of this trial 16. Simultaneous participation in other interventional trials which could interfere with this trial; simultaneous participation in registries and diagnostic trials is allowed 17. Contraindications according to the Summary of Product Characteristics (SmPC): Increased intraocular pressure (primary forms of glaucoma or narrow angle glaucoma), chronic rhinitis sicca 18. Caution and pediatric counselling shall be assured if any of the following conditions are present according to the Summary of Product Characteristics (SmPC): Cardiac insufficiency, arrhythmia, coronary stenosis, hyperthyroidism, stomach or bowel stenosis, bowel paralysis, megacolon, muscle weakness, lung edema, hypersensitivity to atropine, spastic paralysis 19. Parents or children with poor understanding of the German language 20. Person who is in a relationship of dependence/employment with the sponsor or the investigator

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Atropine eye drops, 0.01%
One drop of the above mentioned drug will be installed into each eye daily at bedtime.
Atropine eye drops, 0.02%
One drop of the above mentioned drug will be installed into each eye daily at bedtime.
Placebo (NaCl 0.9%) eye drops
One drop of the above mentioned drug will be installed into each eye daily at bedtime.

Locations

Country Name City State
Germany Augen-Zentrum-Nordwest, Augenpraxis Ahaus Ahaus
Germany Universitäts-Augenklinik Bonn Bonn
Germany Universitätsklinikum Erlangen, Augenklinik Erlangen
Germany Universitätsklinikum Essen, Klinik für Augenheilkunde Essen
Germany Medical Center - University of Freiburg, Eye Hospital Freiburg
Germany Universitätsmedizin Göttingen, Augenklinik Göttingen
Germany Universitätsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Augenheilkunde Hamburg
Germany Medizinische Hochschule Hannover, Klinik für Augenheilkunde Hannover
Germany Universitätsklinikum Heidelberg, Augenklinik Heidelberg
Germany Uniklinik Köln, Zentrum für Augenheilkunde Köln
Germany Universitätsklinikum Leipzig, Klinik und Poliklinik für Augenheilkunde Leipzig
Germany Universitätsklinikum Magdeburg A.ö.R., Universitätsaugenklinik Magdeburg
Germany Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Augenklinik und Poliklinik Mainz
Germany Ludwig-Maximilians-Universität München, Augenklinik und Poliklinik München
Germany Klinik für Augenheilkunde des UKM, Gebäude D15 Münster
Germany Pius-Hospital Oldenburg, Medizinischer Campus Universität Oldenburg, Universitätsklinik für Augenheilkunde Oldenburg
Germany AugenCentrum Rosenheim Rosenheim
Germany Universitätsklinikum Ulm, Klinik für Augenheilkunde Ulm

Sponsors (1)

Lead Sponsor Collaborator
University Eye Hospital, Freiburg

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Other Assessment of rebound of myopia progression (refraction) after cessation of atropine 0.02% treatment Change in refraction [D/year] in year 3, to be determined only in the intervention group. 24-months - 36-months
Other Assessment of rebound of myopia progression (axial length) after cessation of atropine 0.02% treatment Change in axial length [mm/year] in year 3, to be determined only in the intervention group. 24-months - 36-months
Other Change in refraction [D/year] Change in refraction [D/year] after two years of treatment with low-dose atropine 0.02% eye drops (after year 2 in the interventional group) compared to low-dose atropine 0.01% eye drops (after year 3 in the control group). intervention group: baseline - 24-months, control group: 12-months - 36-months
Other Change in axial length [mm/year] Change in axial length [mm/year] after two years of treatment with low-dose atropine 0.02% eye drops (after year 2 in the interventional group) compared to low-dose atropine 0.01% eye drops (after year 3 in the control group). intervention group: baseline - 24-months, control group: 12-months - 36-months
Other Assessment of safety of topical preservative free atropine in comparison to placebo with regard to pupil size Pupil diameter in mm using the IOL Master 500 or 700 or a PlusoptiX device (preferred) at 200 - 300 lux room illumination. Parameter will be listed by site and patient and displayed in summary tables. Baseline - 36-months
Other Assessment of safety of topical preservative free atropine in comparison to placebo with regard to near vision Visual acuity at near (40 cm distance) using Landolt-C near vision charts (non-crowded version) as decimal acuity. Parameter will be listed by site and patient and displayed in summary tables. Baseline - 36-months
Other Assessment of safety of topical preservative free atropine in comparison to placebo with regard to accomodation Accommodation in D as the near point by the Royal air force near point rule (RAF) or by the Accommodation Convergence Rule (VISUS GmbH) (mean of three measurements of both eyes). Parameter will be listed by site and patient and displayed in summary tables. Baseline - 36-months
Other Assessment of safety of topical preservative free atropine in comparison to placebo with regard to pulse rate Pulse rate (per minute): parameter will be listed by site and patient and displayed in summary tables. Baseline - 36-months
Other Number of participants with treatment-related adverse events as assessed by the current CTCAE v4.0 A questionnaire about potential side effects will be completed three times during the study course
A patient diary of potential side effects will be provided for patients/parents or guardians to complete and bring to each study visit
Adverse events will be documented in the eCRF
The adverse events are displayed in summary tables by treatment.
Baseline - 36-months
Primary Demonstration of superiority of low-dose atropine 0.02% eye drops compared to placebo for myopia control Change in cycloplegic refraction [dioptre (D)/year] after one year will be performed using an analysis of covariance (ANCOVA) model with the annual change in refraction as the dependent variable. The mean value of both eyes is analysed. Baseline - 12 months
Secondary Assessment of axial eye length growth under low-dose atropine 0.02% in comparison to placebo Change in axial length [mm/year]. The mean value of both eyes is analysed. Analyses will be performed in a regression model. Baseline - 12 months
Secondary Assessment of the categorized rate of change in refraction of low-dose atropine 0.02% compared to placebo The primary endpoint change in cycloplegic refraction after one year will be categorized (patients progressing < 0.25D (dioptre), 0.25D - 0.75D and > 0.75D after one year of treatment) and will be analysed descriptively, giving absolute and relative frequencies of these categories as a supportive analysis. Baseline - 12 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05919654 - Clinical Evaluation of MyoCare in Europe (CEME) N/A
Recruiting NCT03402100 - Eye Drops Study for Myopia Control in Schoolchildren N/A
Recruiting NCT06088225 - Myopia Preventing With Distance-image Screen N/A
Not yet recruiting NCT06085430 - Kubota Glass Parameter Refinement Study N/A
Not yet recruiting NCT06405711 - To Evaluate the Efficacy and Safety of an Defocus Lens in Slowing the Progression of Myopia N/A
Recruiting NCT05881655 - Slow Myopia Progression With Different Irradiance Light N/A
Recruiting NCT05761379 - Clinical Study of Light Therapy to Control Myopia Progression in Children N/A
Not yet recruiting NCT05760911 - Myopia Prevention Through Monitoring and Motivating Outdoor Activities With Smartwatches N/A
Recruiting NCT04722874 - Repeated Low-Level Red-Light Therapy and Orthokeratology in Fast-progressing Myopia Control N/A
Not yet recruiting NCT06221592 - Differences and Wearing Safety and Comfort of New Defocus Incorporated Multiple Segments Spectacle Lenses N/A
Completed NCT04806698 - Long-term Efficacy of Orthokeratology Contact Lens Wear in Controlling the Progression of Childhood Myopia N/A
Completed NCT04806711 - Eleven Years of Menicon Z Night Contact Lens Wear in Reducing Myopia Progression in Children N/A
Completed NCT04806763 - Myopia Control With Orthokeratology Contact Lenses in Spain N/A
Recruiting NCT05894382 - Double Helix Design Defocus Lens Spectacle (RACE) for Myopia Control N/A
Completed NCT05683535 - Adverse Events Related to Low Dose Atropine
Completed NCT05300321 - DIMS-myopia Progression ADN Axial Length Growth N/A
Withdrawn NCT03519490 - Can Distance Center and Near Center Multifocal Contact Lenses Control Myopia Progression in Children? N/A
Completed NCT05372991 - Safety, Tolerability and Pharmacodynamics Evaluation of CBT-009 Eye Drop Phase 1/Phase 2
Active, not recruiting NCT05373693 - Myopia-control Efficacy by Peripheral Defocus Lens (PDL) N/A
Completed NCT05007626 - Near Horizontal Heterophoria in Chinese Children